Olanib 150 mg (Olaparib)

Introduction

Olanib 150 mg is a pharmaceutical formulation containing the active ingredient olaparib. Olanaib inhibits poly (ADP-ribose) polymerase (PARP). Olanaib is specifically designed for the treatment of certain types of cancer, including ovarian, breast, and pancreatic, especially in individuals with BRCA1 and BRCA2 mutations. Olanaib works by exploiting weaknesses in the DNA repair process of cancer cells and inhibiting the PARP enzyme, which is essential for repairing damaged DNA. Olanaib 150 mg leads to the accumulation of DNA damage, which ultimately leads to the death of cancer cells while sparing normal cells to a greater extent.

Composition and Composition

Olanib 150 mg is available in the form of film-coated tablets, each tablet containing 150 mg of olaparib. It is also accompanied by various excipients that provide stability, bioavailability, and ease of administration. Microcrystalline cellulose, colloidal silicon dioxide, and magnesium stearate are present. Which helps the medicine work better.

Mechanism of action

Olaparib works effectively by inhibiting olaparib, which is a PARP inhibitor. PARP enzymes help repair single-strand DNA breaks via the base excision repair mechanism. Olanib 150 mg Olaparib By inhibiting PARP, olaparib prevents cancer cells from repairing damaged DNA. This normally leads to the accumulation of DNA damage, which ultimately results in cell death, especially in cancer cells with BRCA mutations or other defects in homologous recombination repair (HRR). It exploits the concept of artificial lethality, where two of the DNA repair pathways (i.e., PARP inhibition and BRCA mutation) cause cell death.

Therapeutic Indications

Olanib 150 mg is indicated for the treatment of one or more types of cancer, particularly advanced or metastatic.

Ovarian Cancer: Used as maintenance therapy in adults with advanced ovarian cancer who have responded to platinum-based chemotherapy. It is more effective in patients with BRCA1/BRCA2 mutations or homologous recombination deficiency (HRD).

Breast Cancer: Approved for use in patients with HER2-negative metastatic breast cancer and confirmed germline BRCA mutations.

Prostate Cancer: Indicated for metastatic castration-resistant prostate cancer (mCRPC) with HRR gene mutations.

Pancreatic Cancer: Used as maintenance therapy in patients with metastatic pancreatic cancer harboring BRCA mutations, particularly after response to first-line platinum-based chemotherapy.

Dosage and Administration

Olanib 150 mg dose Cancer treatment type, at the same time each day The adult dose is 300 mg (two 150 mg tablets) taken twice daily. The tablets can be taken with or without food, according to the recommendation. Until the illness gets better or there is intolerable toxicity, treatment should be continued.

Administration Guidelines:

1. Take the pills whole with water, without chewing or crushing them.

2. The tablets may be taken with or without food.

3. You should take the doses around 12 hours apart.

If a dose is missed for any reason, the patient should wait until the next scheduled dose.

Pharmacokinetics

Absorption: Olaparib exhibits good oral bioavailability, with peak plasma concentrations generally achieved within 1 to 3 hours of administration.

Metabolism: Mainly broken down by cytochrome P450 enzymes, especially CYP3A4, in the liver.

Elimination: Excreted primarily via feces (40%) and urine (44%), with an average half-life of approximately 12 hours.

Side effects:

Nausea and diarrhea
Fatigue or weakness
Decreased appetite
Anemia, neutropenia and thrombocytopenia
Dizziness and headache, etc.

Serious side effects:

Renal impairment: Dose adjustment is recommended for patients with moderate renal impairment. In cases of severe renal impairment, olanib is not advised.

Hepatic impairment: should be used with caution in patients with moderate to severe liver dysfunction.

Interactions: Olanib may interact with potent CYP3A inhibitors or inducers, which may affect its efficacy or toxicity profile.

Conclusion

Olanib 150 mg (Olaparib) represents a significant advance in precision oncology. It provides targeted treatment options for patients with BRCA mutations and other HRR deficiencies. This requires careful patient selection, monitoring, and management of potential toxicities. By inhibiting the DNA repair process in cancer cells, olaniib serves as a mainstay of targeted cancer therapy, particularly in ovarian, breast, prostate, and pancreatic cancers.

How to order IEB Pharma medicine…

WhatsApp: You can send a message by clicking on our WhatsApp button, and a customer service representative of ieb Pharma will assist you in placing your order.

Telegram/Messenger/WeChat: If you want to place an order on our Facebook Messenger, Telegram, or WeChat, then you can easily place an order by clicking on our message option button.

Email: You can message us at [email protected] for details about your order. We answer your call as soon as we can.